IMU-838 and Oseltamivir in the Treatment of COVID-19

NCT ID: NCT04516915

Last Updated: 2023-08-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-15
• Study Completion Date: 2022-09-21

Brief Summary

To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) and standard care vs. Oseltamivir and standard care in adult subjects with coronavirus disease (COVID-19)

Detailed Description

The IONIC Protocol describes an overarching trial design to provide reliable evidence on the efficacy of IMU-838 (vidofludimus calcium) when delivered in combination with an antiviral therapy (Oseltamivir) [IONIC Intervention] for confirmed or suspected COVID-19 infection in adult patients receiving usual standard of care.

At present, there are no known treatments for COVID-19. Whilst, the anticipated scale of the epidemic is such that hospitals, and particularly intensive care facilities, may be massively overstretched. As described by a few models of pandemic spread, up to 50% of the adult population may fall sick over a period of 8-12 weeks, of whom around 10% may require hospitalisation. This figure could imply nearly 2 million hospital admissions. Considering this scenario, therapies which may only have a moderate impact on survival or on hospital resources could be worthwhile.

Critically, the present trial design has been developed with consideration of the front-line hospital staff working within an overstretched care system in these unprecedented times. To minimise their burden the protocol is deliberately flexible so that it is suitable for a wide range of settings, allowing:

• a broad range of patients to be enrolled (patient pathway, disease stage or mode of diagnosis)
• Additional sub-studies may be added to provide more detailed information on side effects or sub-categorisation of patient types but these are not the primary objective and are not required for participation.
• To be able to include more sites: the investigators will initiate the trial as a single centre (UHCW) and more sites invited to participate according to the emerging evidence
• The investigator have included 'Exploratory and Secondary objectives' in the protocol however, in consideration of the circumstances the research activities will emulate investigations performed as per standard care/routines care to minimise any burden on the delivery teams.

This is a Phase 2b, randomised, parallel-group, open-label study to assess the efficacy and safety of an oral dose of IMU-838 (22.5 mg twice daily [45 mg/day]) plus Oseltamivir (75mg twice daily [150mg/day]) (IONIC Intervetion) or Oseltamivir alone (75mg twice daily) in hospitalised patients with COVID-19.

Conditions

Covid 19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IMU-838 + Oseltamivir

Loading dose of IMU-838 followed by 22.5mg BID plus Oseltamivir (75mg BID) for 14 days

Group Type: EXPERIMENTAL

IMU-838

Intervention Type: DRUG

IMU-838 twice daily at 22.5mg doses for 14 days

Oseltamivir

Intervention Type: DRUG

Oseltamivir twice daily at 75mg doses for 14 days

Oseltamivir

Oseltamivir (75mg BID) for 14 days

Group Type: ACTIVE_COMPARATOR

Oseltamivir

Intervention Type: DRUG

Oseltamivir twice daily at 75mg doses for 14 days

Interventions

IMU-838

IMU-838 twice daily at 22.5mg doses for 14 days

Intervention Type: DRUG

Oseltamivir

Oseltamivir twice daily at 75mg doses for 14 days

Intervention Type: DRUG

Other Intervention Names

Intervention Arm; Control arm

Eligibility Criteria

Inclusion Criteria

• 1. Male or non-pregnant female patients at least 18 years old 2. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection, either:

• Confirmed cases: prospective participants who test positive to a validated specific SARS-CoV-2 nucleic acid test or has the virus identified by electron microscopy or viral culture, as per local trust policy ≤ 7 days before randomisation.
• Probable/Suspected case: prospective participants who may have been in contact with a confirmed case of COVID-19, AND have mild to severe COVID-19 clinical symptoms AND radio-graphic evidence* of pulmonary infiltrates consistent with COVID-19 disease 3. Moderate to severe COVID-19 requiring hospitalisation defined as: a) Clinical status category 3-5 (inclusive) on the 7-point clinical status category scale as proposed by the World Health Organisation (WHO) master protocol: I. Category 3: hospitalized, no oxygen therapy II. Category 4: hospitalized, oxygen by mask or nasal prongs III. Category 5: hospitalized, non-invasive ventilation or high-flow oxygen *where routinely available, no tests will be requested for research purpose

Exclusion Criteria

Use of the following concomitant medications is prohibited at Screening Visit and throughout the duration of the trial:

1. Use of Oseltamivir for more than 48 hrs prior to the first treatment dose

2. Use of antiviral drugs (e.g. nucleoside analogue reverse-transcriptase inhibitors, protease inhibitors, etc.)

3. History of long-term or concurrent use of mycophenolate mofetil, methotrexate exceeding 17.5 mg weekly

4. Chloroquine or hydroxychloroquine

5. Any medication known to significantly increase urinary elimination of uric acid, in particular lesinurad as well as uricosuric drugs such as probenecid

6. Treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, sorafinib, enasidenib, erlotinib, regorafenib, pazopanib and nilotinib

7. Any drug significantly restricting water diuresis, in particular vasopressin and vasopressin analogues

8. Use of rosuvastatin at daily doses higher than 10 mg

• Allergic or hypersensitivity to the IMU-838, Oseltamivir, or any of the ingredients
• Pregnant or breastfeeding or with intention to become pregnant during the study
• Participants who cannot take trial medication orally at presentation
• Undergoing active chemotherapy or radiotherapy.
• If the attending clinician believes that there is a specific contra-indication to the IONIC intervention.
• Patient has a medical or concomitant disease history preventing them from participating
• Critical patients whose expected survival time < 48-72 hours
• Evidence of pancytopenia or immunosuppression
• Any contraindication to Oseltamivir or standard of care

• Platelet count <100,000/mm³ (<100 x 109/L)
• Total bilirubin > 2 x ULN or ALT or GGT > 5 x ULN
• Elevated indirect (unconjugated) bilirubin >1.2 x ULN (i.e. >1.1 mg/dL)
• Serum uric acid levels at Screening Visit >1.2 x ULN (for women >6.8 mg/dL, for men >8.4 mg/dL)
• Renal impairment defined as estimated glomerular filtration rate ≤45 mL/min/1.73m²
• Decompensated liver cirrhosis (Child-Pugh score B and C)
• History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (New York Heart Association [NYHA] class 3 or 4)
• Cardiac disease resulting in marked limitation of physical activity. Patients are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. NYHA class 4: Cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.
• History or presence of any major medical or psychiatric illness (such as severe depression, psychosis, bipolar disorder), history of suicide attempt, or current suicidal ideation, if any of those conditions in the opinion of the investigator could create undue risk to the patient or could affect adherence with the trial protocol

• Participation in any other interventional clinical trial for an experimental treatment for COVID-19

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Immunic AG

INDUSTRY

Sponsor Role: collaborator

University of Warwick

OTHER

Sponsor Role: collaborator

MODEPHARMA

UNKNOWN

Sponsor Role: collaborator

University Hospitals Coventry and Warwickshire NHS Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University Hospital Coventry and Warwickshire NHS Trust

Coventry, West Midlands, United Kingdom

Countries

United Kingdom

References

Sharma K, Berry L, Vryonis E, Ali A, Lara B, Noufaily A, Parsons N, Bradley C, Haley B, Tabuso M, Arasaradnam RP. Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol. BMJ Open. 2022 Nov 17;12(11):e055205. doi: 10.1136/bmjopen-2021-055205.

Reference Type: DERIVED

PMID: 36396307 (View on PubMed)

Other Identifiers

RA486120

Identifier Type: -

Identifier Source: org_study_id